FDA awards grant to validate in vitro-in vivo extrapolation to Simulations Plus

Simulations Plus (SLP) announced a newly funded grant from the U.S. Food and Drug Administration FDA , secured in partnership with the University of Strathclyde and InnoGI Technologies. The project is expected to improve the understanding of amorphous solid dispersion ASD formulations in different conditions and predict the impact of food and pH-dependent drug-drug interactions DDIs through the combination of novel in vitro testing and mechanistic modeling and simulation. For this award, Professor Hannah Batchelor, through her lab at the University of Strathclyde, will analyze ASD drug products and their respective formulation variants. InnoGI Technologies will then test the different ASD formulations under fasted, fed, and higher gastric pH conditions utilizing the tiny-TIMsg, part of the SurroGUT Platform, in vitro system. Next, physiologically based pharmacokinetic PBPK models will be developed in the GastroPlus platform to link in vitro dissolution with in vivo pharmacokinetic data and develop in vitro-in vivo extrapolations IVIVEs . Finally, virtual bioequivalence VBE trial simulations will be conducted in GastroPlus to assess the clinical performance of ASD formulation variants to validate the approaches. The resulting outcomes are anticipated to help speed up formulation adjustments, reduce costs, and accelerate time-to-market for both innovator and generic ASD products. “We are delighted to be at the forefront of this important research, which has the potential to significantly advance PBPK science and revolutionize how we predict drug product performance,” said Dr. Maxime Le Merdy, Director of PBPK Collaborations at Simulations Plus and principal investigator for this grant. “Developing a novel IVIVE methodology for ASD drug products will play a crucial role in optimizing formulation development, fine-tuning process parameters, and supporting bioequivalence assessments by offering key insights into the factors that impact in vivo performance.” FDA scientific and program staff will actively collaborate with the University of Strathclyde, InnoGI Technologies, and Simulations Plus. Dr. Le Merdy, with assistance from scientists at Simulations Plus, will coordinate the modeling and simulation activities of the contract.